Navigation Links
'Alzheimer protein' seems to slow down neurotransmitter production
Date:8/21/2012

How abnormal protein deposits in the brains of Alzheimer's patients disrupt the signalling between nerve cells has now been reported by researchers in Bochum and Munich, led by Dr. Thorsten Mller from the Medizinisches Proteom-Center of the Ruhr-Universitt, in the journal Molecular and Cellular Proteomics. They varied the amount of APP protein and related proteins associated with Alzheimer's disease in cell cultures, and then analysed how this manipulation affected other proteins in the cell. The result: the amount of APP present was related to the amount of an enzyme that is essential for the production of neurotransmitters and therefore for communication amongst nerve cells.

Proteomics: analysing all the proteins of the cells at once

Amyloid plaques are a characteristic feature of Alzheimer's disease. They consist largely of cleavage products of the so-called amyloid precursor protein APP, which occur in excess in the brains of Alzheimer's patients. What role APP plays in healthy people and why the abnormal accumulation of amyloid disrupts the regular functioning of the brain is still largely unclear. To understand the function of APP, the RUB researchers established a new cell model. The new cells produced only a very small amount of APP. What impact this had on all the other proteins of these cells was examined by the researchers through the use of mass spectrometry, among other things. With this method they identified over 2000 proteins and determined their concentrations. They were looking specifically for molecules whose concentrations in the newly established low-APP cells were different than in the reference cells that contained normal amounts of APP.

Abnormal protein able to curb neurotransmitter production

"One candidate has particularly caught our attention, this being the enzyme methionine adenosyltransferase II, alpha, MAT2A for short", Thorsten Mller said. Among other things, the enzyme is crucially involved in the production of neurotransmitters. Low-APP cells contained less MAT2A than the reference cells. To confirm the connection between the "Alzheimer's protein" APP and the neurotransmitter-producing MAT2A, the team studied tissue samples from the brains of deceased Alzheimer's patients and from healthy individuals. In the tissue of the Alzheimer's patients there was less MAT2A than in the healthy samples. These results suggest that APP and MAT2A concentrations are related and are linked to the synthesis of neurotransmitters. "Our results point to a new mechanism by which the defective cleavage of the APP protein in Alzheimer's disease could be directly related to altered neurotransmitter production", Mller said. "As a result, the signal transduction of nerve cells could be disrupted, which, over an extended period, could possibly also cause the death of cells."


'/>"/>
Contact: Dr. Thorsten Mller
thorsten.t.mueller@rub.de
49-234-322-9265
Ruhr-University Bochum
Source:Eurekalert

Related medicine news :

1. Rejected drug may protect against toxic substance common to Alzheimers and Parkinsons diseases
2. Blood test for Alzheimers gaining ground
3. Alzheimers Progression Slower After 80: Study
4. In Mice, Alzheimers-Linked Protein Shows Promise Against MS
5. Artificial butter flavoring ingredient linked to key Alzheimers disease process
6. Spice ingredient in curry emerges as promising basis for an Alzheimers disease medicine
7. Rejected Alzheimers drug shows new potential
8. Scientists Say Blood Test May Help Predict Alzheimers
9. Helping Alzheimers patients stay independent
10. Alzheimers Drug Shows Promise in Early Trial
11. Alzheimers Treatment Shows Promise in Small, 3-Year Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... PA (PRWEB) , ... December 09, 2016 , ... An ... permit amputees to safely ride all types of amusement park rides. , The patent-pending ... the unit is easy to use and could be set up in a matter ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pennsylvania Cable Network (PCN) during the summer of 2016. The program was made ... by the United States Department of Health and Human Services Administration. The ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate that ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
(Date:12/8/2016)... ... 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services ... Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) named ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... KEY FINDINGS North America ... market in 2016 and is expected to continue in ... a large number of surgical procedures that are taking ... in the patient temperature management market.) Patient warming and ... of blood during surgeries, lowering the risks of neurological ...
(Date:12/8/2016)... , Dec 8, 2016 Research and ... Market Analysis and Trends - Adhesion Type, Application, Usability - Forecast ... ... Global Cardiology Electrodes Market is poised to grow at a CAGR ... trends that the market is witnessing include advancements in extracellular microelectrode ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
Breaking Medicine Technology: